Pharmacokinetics of rifabutin.
We investigated the pharmacokinetics of rifabutin in 15 male patients as part of a phase I trial of the treatment of early symptomatic human immunodeficiency virus infection. Six or more patients were studied at each of four different oral dosage levels: 300, 600, 900, and 1,200 mg/day. Twelve studi...
שמור ב:
| הוצא לאור ב: | Antimicrob Agents Chemother |
|---|---|
| Principais autores: | , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
American Society for Microbiology (ASM)
1989
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC172632/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/2552902/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.33.8.1237 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|
